CAPR Capricor Therapeutics: 5 Stock Signals & Tuesday Predicted Opening Price - Jul29 Advisory? 🚨
1 extracted signal · 1 resolved · 0 still active
StockInvest.usIndependent analyst profile- Source published
- 07 Jul 2026, 10:24 UTC
- Recorded by Tahlil Plus
- 07 Jul 2026, 10:35 UTC
AI-generated source summary
Capricor Therapeutics (CAPR) is currently exhibiting a bearish trend, with multiple technical indicators suggesting a continued decline. The 3-month Moving Average Convergence Divergence (MACD) shows negative signals, and the stock is trading below both its 50-day and 200-day moving averages, which are at $167.08 and $152.36 respectively. This confluence indicates a bearish short-term and long-term forecast. The stock experienced a significant drop of 3.36% on the last trading day, closing at $22.43. The volume on this decline was 2 million shares, which is higher than the average volume, suggesting increased selling pressure. Fundamental analysis indicates a P/E ratio of -9.67 and a negative return on equity and assets, reinforcing the bearish outlook. The stock has also seen a significant decrease of 44.44% over the past 52 weeks. Analysts have also issued negative ratings, with multiple strong sell recommendations. The price is currently below key support and resistance levels, with the next resistance identified at $23.80 and no immediate support found. Given these factors, a further decline to a projected target of $20.43 is expected, with a failure bound at $24.05, which would invalidate the bearish short-term outlook.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Source processing completed
Source analysis and structured extraction completed.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
StockInvest.us
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.